BACKGROUND AND PURPOSE: Transient receptor potential melastatin 7 (TRPM7) is a unique channel kinase which is crucial for various physiological functions. However, the mechanism by which TRPM7 is gated and modulated is not fully understood. To better understand how modulation of TRPM7 may impact biological processes, we investigated if TRPM7 can be regulated by the phospholipids sphingosine (SPH) and sphingosine-1-phosphate (S1P), two potent bioactive sphingolipids that mediate a variety of physiological functions. Moreover, we also tested the effects of the structural analogues of SPH, N,N-dimethyl-D-erythro-sphingosine (DMS), ceramides and FTY720 on TRPM7. EXPERIMENTAL APPROACH: HEK293 cells stably expressing TRPM7 were used for whole-cell, single-channel and macropatch current recordings. Cardiac fibroblasts were used for native TRPM7 current recording. KEY RESULTS: SPH potently inhibited TRPM7 in a concentration-dependent manner, whereas S1P and other ceramides did not produce noticeable effects. DMS also markedly inhibited TRPM7. Moreover, FTY720, an immunosuppressant and the first oral drug for treatment of multiple sclerosis, inhibited TRPM7 with a similar potency to that of SPH. In contrast, FTY720-P has no effect on TRPM7. It appears that SPH and FTY720 inhibit TRPM7 by reducing channel open probability. Furthermore, endogenous TRPM7 in cardiac fibroblasts was markedly inhibited by SPH, DMS and FTY720. CONCLUSIONS AND IMPLICATIONS: This is the first study demonstrating that SPH and FTY720 are potent inhibitors of TRPM7. Our results not only provide a new modulation mechanism of TRPM7, but also suggest that TRPM7 may serve as a direct target of SPH and FTY720, thereby mediating S1P-independent physiological/pathological functions of SPH and FTY720.
BACKGROUND AND PURPOSE: Transient receptor potential melastatin 7 (TRPM7) is a unique channel kinase which is crucial for various physiological functions. However, the mechanism by which TRPM7 is gated and modulated is not fully understood. To better understand how modulation of TRPM7 may impact biological processes, we investigated if TRPM7 can be regulated by the phospholipidssphingosine (SPH) and sphingosine-1-phosphate (S1P), two potent bioactive sphingolipids that mediate a variety of physiological functions. Moreover, we also tested the effects of the structural analogues of SPH, N,N-dimethyl-D-erythro-sphingosine (DMS), ceramides and FTY720 on TRPM7. EXPERIMENTAL APPROACH: HEK293 cells stably expressing TRPM7 were used for whole-cell, single-channel and macropatch current recordings. Cardiac fibroblasts were used for native TRPM7 current recording. KEY RESULTS:SPH potently inhibited TRPM7 in a concentration-dependent manner, whereas S1P and other ceramides did not produce noticeable effects. DMS also markedly inhibited TRPM7. Moreover, FTY720, an immunosuppressant and the first oral drug for treatment of multiple sclerosis, inhibited TRPM7 with a similar potency to that of SPH. In contrast, FTY720-P has no effect on TRPM7. It appears that SPH and FTY720 inhibit TRPM7 by reducing channel open probability. Furthermore, endogenous TRPM7 in cardiac fibroblasts was markedly inhibited by SPH, DMS and FTY720. CONCLUSIONS AND IMPLICATIONS: This is the first study demonstrating that SPH and FTY720 are potent inhibitors of TRPM7. Our results not only provide a new modulation mechanism of TRPM7, but also suggest that TRPM7 may serve as a direct target of SPH and FTY720, thereby mediating S1P-independent physiological/pathological functions of SPH and FTY720.
Authors: Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin Journal: Nat Rev Drug Discov Date: 2010-10-29 Impact factor: 84.694
Authors: Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Donald A Vessey; Michael Kelley; Jianqing Zhang; Luyi Li; Rong Tao; Joel S Karliner Journal: J Biochem Mol Toxicol Date: 2007 Impact factor: 3.642
Authors: Suresh K Mendu; Marta E Stremska; Michael S Schappe; Emily K Moser; Julia K Krupa; Jason S Rogers; Eric J Stipes; Clare A Parker; Thomas J Braciale; Justin S A Perry; Bimal N Desai Journal: Sci Signal Date: 2020-12-08 Impact factor: 8.192
Authors: Mi-Kyung Shin; Candela Caballero Eraso; Yun-Ping Mu; Chenjuan Gu; Bonnie H Y Yeung; Lenise J Kim; Xiao-Ru Liu; Zhi-Juan Wu; Omkar Paudel; Luis E Pichard; Machiko Shirahata; Wan-Yee Tang; James S K Sham; Vsevolod Y Polotsky Journal: Circ Res Date: 2019-09-23 Impact factor: 17.367
Authors: M Germana Sanna; Kevin P Vincent; Emanuela Repetto; Nhan Nguyen; Steven J Brown; Lusine Abgaryan; Sean W Riley; Nora B Leaf; Stuart M Cahalan; William B Kiosses; Yasushi Kohno; Joan Heller Brown; Andrew D McCulloch; Hugh Rosen; Pedro J Gonzalez-Cabrera Journal: Mol Pharmacol Date: 2015-10-22 Impact factor: 4.436
Authors: Maxime G Blanchard; Wararat Kittikulsuth; Anil V Nair; Jeroen H F de Baaij; Femke Latta; Jonathan R Genzen; Donald E Kohan; René J M Bindels; Joost G J Hoenderop Journal: J Am Soc Nephrol Date: 2015-07-06 Impact factor: 10.121
Authors: Rajan Sah; Pietro Mesirca; Marjolein Van den Boogert; Jonathan Rosen; John Mably; Matteo E Mangoni; David E Clapham Journal: Proc Natl Acad Sci U S A Date: 2013-07-22 Impact factor: 11.205